Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 6/20 | 0.49 |
| ▸ | GSK3B | P49841 | 6/20 | 0.49 |
| ▸ | SRPK1 | Q96SB4 | 5/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | PRKX | P51817 | 1/20 | 0.49 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.49 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 9/20 | 0.46 |
| ▸ | HIPK4 | Q8NE63 | 5/20 | 0.46 |
| ▸ | STK3 | Q13188 | 5/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.46 |
| ▸ | CDK8 | P49336 | 4/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14960342 | 0.86 | GSK3A (0.48) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL13170010 | 0.82 | KDM4E (0.56) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL1621426 | 0.81 | RORC (0.49) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL16359172 | 0.80 | GSK3A (0.44) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL1464507 | 0.80 | TAS2R14 (0.52) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL2635287 | 0.80 | TAS2R14 (0.57) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL10068190 | 0.79 | GRM5 (0.45) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL1621558 | 0.79 | RORC (0.53) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL1464461 | 0.79 | CNR2 (0.49) | GSK3AGSK3BSRPK1AURKAPRKX | |
| SCHEMBL29640129 | 0.79 | P2RX7 (0.53) | GSK3AGSK3BSRPK1AURKAPRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | disclosed |
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299111-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| EP-2081905-B1 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20110130431-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130431-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039645-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | WO | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008014199-A2 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | CNR2, CNR1, OPRL1 | GSK3A 3446/4885GSK3B 3690/4885SRPK1 3549/4885 |
| US-20110130431-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | GSK3A 2084/4885GSK3B 1888/4885SRPK1 4247/4885 |
| US-20080039464-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | GSK3A 2200/4885GSK3B 1984/4885SRPK1 4263/4885 |
| US-20110071127-A1 | Compounds Which Modulate the CB2 Receptor | CNR2, CNR1, OPRL1 | GSK3A 2084/4885GSK3B 1888/4885SRPK1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.